Akero Therapeutics Inc

-2.12 (-5.27%)
5:00:00 PM EDT: $40.23 +2.12 (+5.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Akero Therapeutics Inc Stock, NASDAQ:AKRO

601 Gateway Boulevard, Suite 350, South San Francisco, California 94080-7006
United States of America
Phone: +1.650.487.6488
Number of Employees: 38


Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.